Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease

Gastroenterology - United Kingdom
doi 10.1053/j.gastro.2018.05.039
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients With Hepatocellular Carcinoma

Targeted Oncology
Cancer ResearchOncologyPharmacology
2017English

Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients With Hepatocellular Carcinoma

Journal of Hepatology
Hepatology
2017English

Development and Validation of a Scoring System to Identify Patients With Microscopic Colitis

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2015English

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

Gastroenterology
HepatologyGastroenterology
2019English

Development of a Disease Severity Scoring System for Patients With Pompe Disease

Pediatric Rheumatology
ImmunologyPediatricsRheumatologyAllergyPerinatologyChild Health
2008English

The Development and Validation of a Novel Canine Mucosal Endoscopic Scoring System Applied to Dogs With Inflammatory Bowel Disease

English

A Comparative Study of AIMS 65 Score With Other Scoring Systems to Predict Outcomes in Patients With Upper GI Bleed in Chronic Liver Disease

International Journal of Contemporary Medical Research [IJCMR]
2019English

Psy114 - Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy in Patients With Crohn’s Disease in the United Kingdom (Uk)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pgi21 - Cost-Effectiveness Analysis of Ustekinumab Versus Adalimumab, Infliximab and Vedolizumab for the Treatment of Patients With Moderately to Severe Active Crohn’s Disease for Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy